|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
2
|
|
gptkbp:bfsParent
|
gptkb:physicist
|
|
gptkbp:acquisition
|
gptkb:Nant_Cell,_Inc.
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:can_lead_to
|
gptkb:Nant_Kwest-16
NK cell therapy
|
|
gptkbp:ceo
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:clinical_trial
|
Phase 2
hundreds
positive outcomes
promising results
adaptive trial design
various cancer therapies
Phase 1, Phase 2
multiple sites in the US
|
|
gptkbp:collaborations
|
various pharmaceutical companies
various institutions
|
|
gptkbp:community_engagement
|
active in local communities
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:financial_performance
|
growing revenue
|
|
gptkbp:focus
|
gptkb:vaccine
|
|
gptkbp:founded
|
gptkb:2015
|
|
gptkbp:founder
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:future_plans
|
expand into international markets
|
|
gptkbp:headquarters
|
gptkb:Culver_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nant Kwest, Inc.
|
|
gptkbp:industry
|
healthcare
|
|
gptkbp:innovation
|
cutting-edge technology
|
|
gptkbp:invention
|
numerous patents in immunotherapy
|
|
gptkbp:investment
|
various venture capital firms
cancer immunotherapy
transparent communication
$100 million (2021)
|
|
gptkbp:ipo
|
gptkb:2015
|
|
gptkbp:market
|
leading position in immunotherapy.
|
|
gptkbp:market_cap
|
$1 billion (2021)
|
|
gptkbp:marketing_strategy
|
innovation in cancer treatment
|
|
gptkbp:net_worth
|
-$50 million (2020)
|
|
gptkbp:part_of
|
gptkb:Nant_Works
|
|
gptkbp:partnerships
|
academic institutions
key industry players
|
|
gptkbp:philanthropy
|
support cancer research initiatives
|
|
gptkbp:platform
|
Nant technology platform
|
|
gptkbp:products
|
NK cell therapies
|
|
gptkbp:publishes
|
numerous scientific publications
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
ongoing submissions
|
|
gptkbp:research_and_development
|
significant investment
multiple therapies
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
|
|
gptkbp:revenue
|
$10 million (2020)
|
|
gptkbp:staff
|
leading experts in oncology
|
|
gptkbp:strategic_importance
|
expand product pipeline
|
|
gptkbp:subsidiary
|
gptkb:Nant_Cell,_Inc.
|
|
gptkbp:symbol
|
NK
|
|
gptkbp:team
|
experienced professionals
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:type_of_care
|
focus on patient needs
|
|
gptkbp:website
|
www.nantkwest.com
|